Truist Securities updated its financial outlook for Ally Financial Inc. (NYSE: NYSE:ALLY), increasing the price target from ...

Truist Securities began coverage on Chemours shares (NYSE:CC) with a Buy rating and a price target of $27.00. The $2.85 billion market cap company, which currently trades at a P/E ratio of 37.3, ...

APi Group, which entered the public market through a SPAC in 2019, has established itself as a leader in the U.S. fire protection sector. According to Truist Securities, the company is well ...

Kim Hye-min, a Research Institute at KB Securities, stated that “the 180,000-liter capacity of plant 4 has been operational since June 2023, and the ratio of raw material sales (DS) from plants ...

Four years after its launch, US sales of Xbox Series X/S are trailing behind those of its predecessor, Xbox One, at the same point in the consoles' life time. Sales of PlayStation 5, however ...

Sales of existing homes in the US fell last year to the lowest level ... according to a recent Freddie Mac estimate. In December, inventory stood at 1.15 million units, down 13.5% from November ...

On Wednesday, Truist Securities provided insights into the AI ... InvestingPro offers comprehensive research reports covering over 1,400 US stocks, including detailed financial health metrics ...

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on LEGN stock, giving a Buy rating yesterday.Invest with Confidence: ...

NG Energy International Corp. (CVE:GAS – Free Report) – Equities researchers at Clarus Securities cut their FY2024 earnings estimates for NG Energy International in a report released on ...

J&J Beats Quarterly Sales and Profit Estimates on Cancer Drug Sales By Patrick ... as the drugmaker launches new products to counter U.S. competition from close copies of its blockbuster psoriasis ...

(Reuters) - Procter & Gamble beat second-quarter sales estimates on Wednesday, as the Pantene shampoo maker's efforts to bring newer versions of its products to the market across various price ...

Several Stelara biosimilars are expected to launch in the U.S. this year ... more than 18% of J&J's total drug sales of $56.96 billion for 2024 and missing estimates of $10.59 billion.